Igor Correia de Almeida
Corporate Officer/Principal chez SeneXta Therapeutics SA
Profil
Igor Correia de Almeida is currently the Director-Executive Board at SeneXta Therapeutics SA since 2008 and an Associate Professor at The University of Texas at Austin since 2004.
He was previously an Assistant Professor at the University of Sao Paulo from 1999 to 2004 and a Lecturer at Einstein Albert Jewish Hospital Nursing School from 1989 to 1993.
He received his graduate degree from the University of Sao Paulo in 1989, his doctorate from the same institution in 1994, and his undergraduate degree from the University of Brasília in 1981.
Postes actifs de Igor Correia de Almeida
| Sociétés | Poste | Début |
|---|---|---|
SeneXta Therapeutics SA
 SeneXta Therapeutics SA Medical SpecialtiesHealth Technology SeneXta Therapeutics SA engages in the research and development of therapies for neurodegenerative disorders. The firm provides medicines that maintain healthy brain ageing and rehabilitation after ischemic brain injury. The company was founded by Enrico Braglia and Federica Pericle in 2008 and is headquartered in Lugano, Switzerland. | Corporate Officer/Principal | 18/09/2009 |
| The University of Texas at Austin | Corporate Officer/Principal | 18/09/2009 |
Anciens postes connus de Igor Correia de Almeida
| Sociétés | Poste | Fin |
|---|---|---|
| University of Sao Paulo | Corporate Officer/Principal | 01/10/2004 |
| Einstein Albert Jewish Hospital Nursing School | Corporate Officer/Principal | 01/03/1993 |
Formation de Igor Correia de Almeida
| University of Sao Paulo | Graduate Degree |
| University of Brasília | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
SeneXta Therapeutics SA
SeneXta Therapeutics SA Medical SpecialtiesHealth Technology SeneXta Therapeutics SA engages in the research and development of therapies for neurodegenerative disorders. The firm provides medicines that maintain healthy brain ageing and rehabilitation after ischemic brain injury. The company was founded by Enrico Braglia and Federica Pericle in 2008 and is headquartered in Lugano, Switzerland. | Health Technology |
| Einstein Albert Jewish Hospital Nursing School |
